ResMed Inc.
NYSE:RMDMedical - Devices
+$1.58 today
- Market cap
- $34.12B
- Beta
- 0.78
- P/E (TTM)
- 18.1
- EPS (TTM)
- $10.37
- Dividend yield
- 1.28%
Volume 1.22M
Average 1.32M
RMD Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
ResMed Inc.NYSE: RMD
Net Receivables · Q4 FY2026 · quarter ended Jun 2026
Net receivables rises 4.6% from a year ago
Net receivables stood at $1.04B at the end of Q4 FY2026, up 4.6% from a year earlier and down 0.9% from the prior quarter. Over 3 fiscal years it compounded at +13.7% a year.
Context
- Net receivables amounted to 11.6% of total assets at the end of Q4 FY2026, down 0.6 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +4.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2026
- 1.04B USD
- Year-over-year change
- +4.6%
- 4-year CAGR
- +15.8%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 1.04B | +4.6% |
| FY2025 | 2025-06-30 | 990.67M | +18.3% |
| FY2024 | 2024-06-30 | 837.28M | +18.8% |
| FY2023 | 2023-06-30 | 704.91M | +22.4% |
| FY2022 | 2022-06-30 | 575.95M | — |
Net Receivables vs competitors
How RMD compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +4.6% is the 5th highest of 9, against a peer median of -2.6%.
- Net receivables amounts to 11.6% of total assets for RMD, versus a peer median of 9.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.88B USD | -13.3% | -0.3% | 10.4% | |
| Jun 2026 | €3.6B EUR | +8.1% | -8.8% | 13.5% | |
| Jun 2026 | $3.05B USD | +8.3% | +14.1% | 6.7% | |
| Sep 2026 | $1.72B USD | +24.4% | +14.9% | 8.9% | |
| Jun 2026 | $1.04B USD | +4.6% | +13.7% | 11.6% | |
| Jun 2026 | $364.61M USD | -29.0% | -5.4% | 5.4% | |
| Jul 2026 | $224M USD | -96.4% | +3.5% | 0.2% | |
| Jun 2026 | $103.34M USD | -24.9% | +25.0% | 11.2% | |
| Mar 2026 | $28.25M USD | +10.8% | +6.4% | 47.5% | |
| Peer median (excluding RMD) | — | -2.6% | +4.9% | 9.7% | |
Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 273.71M | 227.89M | 238.36M | 1.21B | 1.47B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 575.95M | 704.91M | 837.28M | 990.67M | 1.04B |
| Inventory | 743.91M | 998.01M | 822.25M | 927.71M | 945.81M |
| Other Current Assets | 131.27M | 179.93M | 180.01M | 164.5M | 457.39M |
| Total Current Assets | 1.93B | 2.37B | 2.36B | 3.51B | 4.32B |
| Property, Plant & Equipment (Net) | 630.5M | 665.81M | 699.15M | 718.29M | 735M |
| Goodwill | 1.94B | 2.77B | 2.84B | 3.05B | 3.36B |
| Intangible Assets | 345.94M | 552.34M | 485.9M | 464.86M | 0 |
| Long-term Investments | 67.22M | 156.89M | 169.77M | 85.03M | 0 |
| Tax Assets | 79.75M | 132.97M | 203.57M | 253.12M | 543.9M |
| Other Non-current Assets | 104.53M | 105.56M | 114.24M | 100.81M | 0 |
| Total Non-current Assets | 3.16B | 4.38B | 4.51B | 4.67B | 4.64B |
| Total Assets | 5.1B | 6.75B | 6.87B | 8.17B | 8.97B |
| Account Payables | 159.25M | 150.76M | 237.73M | 278.16M | 308.92M |
| Short-term Debt | 9.92M | 9.9M | 9.9M | 9.9M | 259.95M |
| Tax Payables | 44.89M | 72.22M | 107.52M | 0 | 98.11M |
| Deferred Revenue | 108.67M | 138.07M | 152.55M | 166.03M | 162.91M |
| Other Current Liabilities | 1.95M | 9.56M | 4.65M | 2.7M | 41.16M |
| Total Current Liabilities | 689.3M | 758.53M | 910.66M | 1.02B | 1.4B |
| Long-term Debt | 765.33M | 1.43B | 697.31M | 658.39M | 399.42M |
| Deferred Tax Liabilities | 9.71M | 90.65M | 79.34M | 77.68M | 64.64M |
| Deferred Revenue (Non-current) | 95.46M | 119.19M | 137.34M | 156.8M | 170.95M |
| Other Non-current Liabilities | 54.86M | 105.35M | 42.26M | 141.52M | 213.03M |
| Total Non-current Liabilities | 1.05B | 1.86B | 1.1B | 1.19B | 985.45M |
| Total Liabilities | 1.74B | 2.62B | 2.01B | 2.21B | 2.38B |
| Common Stock | 586K | 588K | 588K | 761K | 764K |
| Retained Earnings | 3.61B | 4.25B | 4.99B | 6.08B | 7.26B |
| Accumulated OCI | (312.75M) | (272.53M) | (251.53M) | (74.7M) | (82.52M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.36B | 4.13B | 4.86B | 5.97B | 6.59B |
| Total Debt | 917.55M | 1.58B | 873.94M | 851.81M | 825.92M |
| Net Debt | 643.84M | 1.35B | 635.57M | (357.64M) | (643.32M) |
ResMed Inc.
NYSE:RMD
Intrinsic Alpha fair value
Locked
Current Price
$242.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.